Medical Oncologist

Research Group Home Page: 

Work address: 

Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.

E-pub date: 30 Sep 2019

Quantifying normal human brain metabolism using hyperpolarized [1-13C]pyruvate and magnetic resonance imaging.

E-pub date: 31 Dec 2018

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.

E-pub date: 30 Jun 2018

Hyperpolarized carbon-13 magnetic resonance spectroscopic imaging: a clinical tool for studying tumour metabolism.

E-pub date: 31 May 2018

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.

E-pub date: 20 Mar 2018

Drug development and clinical trial design in pancreatico-biliary malignancies.

E-pub date: 01 Jan 2018

Early Phase Clinical Trial Designs – State of Play and Adapting for the Future.

E-pub date: 31 Dec 2017

Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study.

E-pub date: 31 Dec 2016

Intensive cisplatin/oral etoposide for epithelial ovarian cancer: the Cambridge Gynae-Oncology Centre experience: too toxic for relapse?

E-pub date: 31 Mar 2016

Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.

E-pub date: 31 Aug 2015

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

E-pub date: 01 Aug 2015

Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.

E-pub date: 31 Jul 2015

Progress in pancreatic cancer: moving beyond gemcitabine?

E-pub date: 31 Aug 2012

Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials.

E-pub date: 01 Aug 2012

The role of angiogenesis inhibitors in the management of melanoma.

E-pub date: 01 Aug 2012

PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer.

E-pub date: 31 Jul 2012

Combining antiangiogenics to overcome resistance: rationale and clinical experience.

E-pub date: 30 Jun 2012

Targeting the DNA damage response in oncology: past, present and future perspectives.

E-pub date: 31 May 2012

Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain.

E-pub date: 01 Feb 2012

Targeting angiogenesis in melanoma: prospects for the future.

E-pub date: 01 Nov 2010

A phase 2 study of vatalanib in metastatic melanoma patients.

E-pub date: 31 Oct 2010

Targeting insulin-like growth factor signaling: rational combination strategies.

E-pub date: 01 Sep 2010

Perspectives in drug development for metastatic renal cell cancer.

E-pub date: 01 Jun 2010

Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.

E-pub date: 31 Mar 2010

Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies.

E-pub date: 01 Nov 2009

Development of a Prognostic Model That Predicts Survival After Pancreaticoduodenectomy for Ampullary Cancer.

E-pub date: 01 Jan 1970

Show all